Biofrontera AG Return on Equity

Biofrontera AG (B8FK.DE) currently reports a ROE of -106.87%. That is below the Healthcare sector average of -75.59%. Use the charts on this page to explore Biofrontera AG's ROE history and peer comparisons.

Biofrontera AG's ROE of -106.87% is lower than the Healthcare sector average of -75.59%. That is roughly 41.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Biofrontera AG's current -106.87% should be judged against Healthcare norms (sector average: -75.59%) and against B8FK.DE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -106.87%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for Biofrontera AG, and consider following B8FK.DE for alerts when major investors trade the stock.

Biofrontera AG is classified in the Healthcare sector. On ROE, it currently shows -106.87% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing B8FK.DE with unrelated industries.